Gastrointestinal Tract - Original Article

High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection

Volume 31 · Issue 3 Publish Date: March 15, 2020
Full Text PDF
DOI
Kadir Öztürk
Department of Gastroenterology, Gülhane Military Medical Academy, Ankara, Turkey
Ömer Kurt
Department of Gastroenterology, Gülhane Military Medical Academy, Ankara, Turke
Gürkan Çelebi
Department of Gastroenterology, Gülhane Military Medical Academy, Ankara, Turkey
Hakan Şarlak
Department of Gastroenterology, Gulhane School of Medicine, Ankara, Turkey
Muhammed Fatih Karakaya
Department of Gastroenterology, Gulhane School of Medicine, Ankara, Turkey
Hakan Demirci
Department of Gastroenterology, Gülhane Military Medical Academy, Ankara, Turkey
Ali Kılınç
Department of Gastroenterology, Gulhane School of Medicine, Ankara, Turkey
Ahmet Uygun
Departments of Gastroenterology, Gülhane Military Medical Academy, Ankara
Öztürk, K., Kurt, Ömer, Çelebi, G., Şarlak, H., Karakaya, M. F., Demirci, H., … Uygun, A. (2020). High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turkish Journal of Gastroenterology, 31(3), 234–238. https://doi.org/10.5152/tjg.2020.18974
Full Text Full Text PDF

Abstract

Background/Aims: Although many regimens, including quadruple, sequential, and concomitant treatment, are used and recommended as first-line or rescue therapies for Helicobacter pylori infection, eradication rates are still below 90% in intention-to-treat analyses. Treatment protocols with substantially high eradication rates and low antibiotic resistance are needed. In this study, we investigated the efficacy of high-dose dual therapy as first-line treatment in a Turkish population. Materials and Methods: All patients underwent upper gastrointestinal endoscopy for the initial H. pylori status because of dyspeptic symptoms. All patients received a 14-day, high-dose dual therapy comprising rabeprazole (20 mg t.i.d.) and amoxicillin (1 g t.i.d.) for H. pylori eradication. H. pylori stool antigen tests of eradication were administered to all participants at least 4 weeks after the completion of the treatment. Results: The high-dose dual therapy demonstrated a 91.3% rate of successful eradication of H. pylori infection. Per-protocol success was 94.4% among female patients (n=51) and 89.6% among male patients (n=86); in terms of gender, the differences were not significant (p=0.310). No side effects were observed during the study in any patient. Six other patients did not take adequate doses of the treatment protocol. Conclusion: High-dose dual therapy with rabeprazole and amoxicillin was highly effective and well tolerated as a first-line therapy for H. pylori eradication.

Most read articles by the same author(s)

1 2 3 > >> 
Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 31 · Issue 3
Pages 234-238
History
Published Online March 15, 2020
Copyright
Affiliations
Kadir Öztürk
Department of Gastroenterology, Gülhane Military Medical Academy, Ankara, Turkey
Ömer Kurt
Department of Gastroenterology, Gülhane Military Medical Academy, Ankara, Turke
Gürkan Çelebi
Department of Gastroenterology, Gülhane Military Medical Academy, Ankara, Turkey
Hakan Şarlak
Department of Gastroenterology, Gulhane School of Medicine, Ankara, Turkey
Muhammed Fatih Karakaya
Department of Gastroenterology, Gulhane School of Medicine, Ankara, Turkey
Hakan Demirci
Department of Gastroenterology, Gülhane Military Medical Academy, Ankara, Turkey
Ali Kılınç
Department of Gastroenterology, Gulhane School of Medicine, Ankara, Turkey
Ahmet Uygun
Departments of Gastroenterology, Gülhane Military Medical Academy, Ankara
Cite this Article
Öztürk, K., Kurt, Ömer, Çelebi, G., Şarlak, H., Karakaya, M. F., Demirci, H., … Uygun, A. (2020). High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turkish Journal of Gastroenterology, 31(3), 234–238. https://doi.org/10.5152/tjg.2020.18974
Outlines